Convenience Claims Can Put Companies On Slippery Promotional Ground
FDA cites an ad for Sanofi-Aventis' prostate cancer therapy Eligard for implying better patient quality of life and more physician efficiency because of less-frequent injections.
More from Archive
More from Pink Sheet
• By
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
• By
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
• By
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.